Chrysos Corporation Ltd (ASX: C79) shares are having a strong session on Wednesday.

In early trade, the ASX All Ords stock was up 9% to $5.40.

The mining technology company's shares have pulled back a touch since then but remain up almost 5% to $5.19 at the time of writing.

Why is this ASX All Ords stock jumping?

Investors have been fighting to get hold of the company's shares after it revealed "significant sales success" during the second quarter of FY 2025.

According to the release, unaudited revenue was up 12% quarter on quarter and 53% year on year to $15.3 million. This was driven primarily by international revenue and sample volume growth.

Chrysos' flagship product is PhotonAssay. It delivers faster, safer, more accurate and environmentally friendly analysis of gold, silver, copper, and other elements.

Management revealed that sample volumes totalled 1.6 million, reflecting 18% growth quarter on quarter and 53% growth year on year.

Also supporting its growth were two contracts signed with OceanaGold Corporation and SGS. They built on four contracts in the first quarter of FY 2025, bringing the total number of contracted units to 56. Though, only 34 units are currently deployed.

There was no earnings update with the release, but management did provide investors with its cash flow statement. It revealed that it recorded cash receipts of $11.7 million from PhotonAssay customers. This led to net operating cash inflows for the quarter totalling $1.5 million.

At the end of the period the ASX All Ords stock had a cash position of $26.6 million and $95 million in undrawn debt available. Management believes this means it is well-funded to support continued PhotonAssay unit growth.

Guidance reaffirmed

The ASX All Ords stock's managing director and CEO, Dirk Treasure, was pleased with the quarter. He commented:

Our significant sales success continued into the second Quarter of FY25 with two new contracts signed, building on four new contracts in the first Quarter. This momentum reflects the ongoing market penetration of our PhotonAssay technology and the efficacy of our customer diversification strategy. Similarly, sample volumes grew a healthy 18% Quarter-on-Quarter, signaling strong market uptake across our mining and laboratory customers in key mining hubs.

In light of its strong first half, Treasure has reaffirmed the company's FY 2025 revenue and earnings guidance. He adds:

Increased sample volumes, together with our growing international unit footprint have driven 12% Quarter-on-Quarter revenue growth. We remain on track to achieve our FY25 guidance of $60-$70m in revenue and $9-$19m in EBITDA. With PhotonAssay units deployed across multiple geographies, we continue to monitor market indicators for signs of a broader improvement in the gold industry cycle and are ready to capture this upside through latent unit capacity.